Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5
Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek
Express News | Veru Inc - Topline Results From Phase 2B Quality Trial Expected in January 2025
Express News | Veru Inc - Enobosarm Generally Well-Tolerated With No Increase in Gastrointestinal Side Effects
Express News | Veru To Present Meta-Analysis of 4 Previous Randomized Clinical Trials That Support Potential Of Enobosarm To Optimize Weight Loss At ObestiyWeek
"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.
Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.
